Abstract:Metastatic recurrence following curative-intent pancreatic cancer surgery is a major clinical problem as nearly all die of this at both early and latent periods following surgery. Latent recurrences are due to reactivation of dormant tumor cells that disseminate before the primary tumor has been removed. The mechanisms that drive cancer dormancy are poorly understood in part because of the lack of animal models that recapitulate the biology of the resected patient. Here we introduce a novel mouse model of pancreatic cancer dormancy in which we establish distal pancreatic tumors by orthotopic injection, resect them four weeks later and then follow the mice for recurrence. We observed recurrence patterns and survival outcomes that mimic human patients undergoing surgery for pancreatic cancer where two thirds of the mice succumb to early metastatic recurrence (median survival 26 days) and one third of the mice (called dormant mice) live substantially long (median survival 554 days) without clinical evidence of disease yet harbor disseminated tumor cells in most organs of the body. Disseminated tumor cells isolated from the livers of dormant mice were quiescent, exhibited stem cell properties and upregulated the expression of Dec2, a transcriptional repressor previously best known for its importance in maintaining circadian rhythms. Dec2 enabled the dormant tumor cells to evade the immune system by reducing the amount of MHC1 on their surfaces, and thereby lowered the number of CD8+ T cells within the tumor microenvironment. Knocking out Dec2 significantly improved the overall survival of immunocompetent mice and increased CD8+ T cell tumor infiltration. The decrease in cell surface MHCI was likely due to impaired surface localization of the protein. RNA-seq analysis demonstrated a loss of antigen presentation pathway genes in Dec2 WT cells, particularly in genes encoding subunits of the proteasome. Proper localization of MHC1 is known to depend upon proteasome-generated peptides. By cut-and-run analysis, Dec2 bound directly to the promoters of a number of proteasomal genes, lowered expression of these genes, and decreased proteasomal activity. These studies describe a new mechanism for Dec2 in regulating cancer dormancy through its downregulation of proteasomal activity which in turn converts a hot to a cold TME by decreasing cell surface MHC1. Citation Format: Lan Wang, Orjola Prela, Ching-Hua Shih, Juliana Cazarin de Menezes, Brian Altman, Paula Vertino, Chris Harris, Darren Carpizo. The circadian rhythm gene Dec2 promotes pancreatic cancer dormancy by facilitating immune evasion [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Pancreatic Cancer; 2023 Sep 27-30; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(2 Suppl) nr C033.

The circadian gene Dec2 promotes pancreatic cancer dormancy by regulating tumor cell antigen presentation to facilitate immune evasion

Abstract C033: The circadian rhythm gene Dec2 promotes pancreatic cancer dormancy by facilitating immune evasion

Abstract 5624: Dec2, a circadian rhythm gene facilitates pancreatic cancer dormancy through evasion of antitumor immunity

Abstract PR-12: The circadian rhythm gene Dec2 regulates multiple components of the antigen presentation pathway to promote pancreatic cancer dormancy by immune evasion

The Circadian Rhythm and Core Gene Period2 Regulate the Chemotherapy Effect and Multidrug Resistance of Ovarian Cancer Through the PI3K Signaling Pathway.

Abstract C019: The circadian master regulator BMAL1 blocks immune cell recognition of pancreatic ductal adenocarcinomas by reducing proteasome activity and MHC1 cell surface localization

Dendritic cells direct circadian anti-tumor immune responses

CircNEIL3 Regulatory Loop Promotes Pancreatic Ductal Adenocarcinoma Progression Via Mirna Sponging and A-to-I RNA-editing

Inhibition of DEC2 is necessary for exiting cell dormancy in salivary adenoid cystic carcinoma

Circadian control of tumor immunosuppression affects efficacy of immune checkpoint blockade

AINTEGUMENTA Promotes Petal Identity and Acts as a Negative Regulator of AGAMOUS

nSMase2-mediated exosome secretion shapes the tumor microenvironment to immunologically support pancreatic cancer

Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer Microenvironment

Abstract C020: Unconvering the hidden immunosuppressive landscape in pancreatic ductal adenocarcinoma

Senescence Defines a Distinct Subset of Myofibroblasts That Orchestrates Immunosuppression in Pancreatic Cancer

Macrophage proliferation machinery leads to PDAC progression, but susceptibility to innate immunotherapy

CircRREB1 Mediates Metabolic Reprogramming and Stemness Maintenance to Facilitate Pancreatic Ductal Adenocarcinoma Progression

Immunoregulation related gene of CSMD2 and RNA activity as potential predicter of 2-year survival in pancreatic cancer: A DNA and RNA sequencing analysis.

Pancreatic cancer ductal cell of origin drives CD73-dependent generation of immunosuppressive adenosine

Antitumor T-cell Immunity Contributes to Pancreatic Cancer Immune Resistance

CircUBAP2-mediated Competing Endogenous RNA Network Modulates Tumorigenesis in Pancreatic Adenocarcinoma.